Foundry Partners LLC purchased a new position in Guardian Pharmacy Services, Inc. (NYSE:GRDN - Free Report) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 100,000 shares of the company's stock, valued at approximately $1,680,000. Foundry Partners LLC owned about 0.16% of Guardian Pharmacy Services at the end of the most recent quarter.
A number of other large investors have also made changes to their positions in GRDN. Stephens Inc. AR purchased a new position in shares of Guardian Pharmacy Services in the 3rd quarter valued at approximately $189,000. Royce & Associates LP purchased a new stake in Guardian Pharmacy Services in the third quarter valued at approximately $1,260,000. Seven Grand Managers LLC acquired a new position in Guardian Pharmacy Services in the 3rd quarter worth approximately $2,515,000. Finally, Allspring Global Investments Holdings LLC purchased a new position in Guardian Pharmacy Services during the 3rd quarter worth approximately $5,460,000.
Wall Street Analyst Weigh In
A number of analysts have recently commented on the company. Truist Financial upped their target price on Guardian Pharmacy Services from $22.00 to $24.00 and gave the stock a "buy" rating in a research note on Friday, November 15th. Raymond James began coverage on Guardian Pharmacy Services in a research report on Monday, October 21st. They issued an "outperform" rating and a $21.00 price objective on the stock. Finally, Stephens initiated coverage on shares of Guardian Pharmacy Services in a research note on Tuesday, October 22nd. They issued an "overweight" rating and a $21.00 target price for the company.
Check Out Our Latest Report on Guardian Pharmacy Services
Guardian Pharmacy Services Stock Performance
GRDN traded up $1.01 on Friday, reaching $23.08. 162,806 shares of the company's stock were exchanged, compared to its average volume of 155,961. Guardian Pharmacy Services, Inc. has a twelve month low of $14.16 and a twelve month high of $23.35.
Guardian Pharmacy Services (NYSE:GRDN - Get Free Report) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($2.00) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.19 by ($2.19). The company had revenue of $314.39 million during the quarter, compared to analysts' expectations of $303.21 million. As a group, sell-side analysts predict that Guardian Pharmacy Services, Inc. will post 0.86 earnings per share for the current year.
Insiders Place Their Bets
In other Guardian Pharmacy Services news, Director Steven D. Cosler bought 7,000 shares of Guardian Pharmacy Services stock in a transaction that occurred on Tuesday, November 19th. The shares were purchased at an average cost of $21.22 per share, for a total transaction of $148,540.00. Following the completion of the transaction, the director now owns 17,713 shares of the company's stock, valued at $375,869.86. This represents a 65.34 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Thomas J. Salentine, Jr. acquired 35,714 shares of the business's stock in a transaction dated Friday, September 27th. The stock was purchased at an average price of $14.00 per share, for a total transaction of $499,996.00. Following the completion of the acquisition, the director now owns 35,714 shares in the company, valued at approximately $499,996. This trade represents a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here.
About Guardian Pharmacy Services
(
Free Report)
Guardian Pharmacy Services, Inc, a pharmacy service company, provides a suite of technology-enabled services designed to help residents of long-term health care facilities (LTCFs) in the United States. Its individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities and behavioral health facilities and group homes.
See Also
Before you consider Guardian Pharmacy Services, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Guardian Pharmacy Services wasn't on the list.
While Guardian Pharmacy Services currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.